Phaseline

Companies › Cellid

Cellid: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Infectious disease, Vaccines; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AdCLD-CoV19-1 OMI
Adenoviral vector-based COVID-19 vaccine (Omicron variant)
–Phase 3COVID-19–
BVAC-E6E7
HPV E6/E7-targeting immunotherapeutic vaccine
E6, E7Phase 1Head and Neck Squamous Cell Carcinoma (HNSCC)Mar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05993325AdCLD-CoV19-1 OMIPhase 3COVID-19VaccinesMar 2025
NCT06797986BVAC-E6E7Phase 1Head and Neck Squamous Cell Carcinoma (HNSCC)Infectious diseaseMar 2027

Targets

E6 (1) E7 (1)

Companies with the same targets

–

Companies built like this

Vaxcyte Dynavax Technologies Aribio Lab Guangzhou Patronus Biotech SK Bioscience

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.